Table 1

Single dose studies of the effects of angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists on renal function, urine output, and sodium excretion

Author/year No patients Ascites Drug dose (mg) Urinary Na output Creatinine clearance or GFR (ml/min) Urine volume MAP (mm Hg)
Girgrah, 200026 9NoLosartan 7.5 orally154 (8) to 202 (12) mmol/day1-150 90 (9) to 92 (11)NA88 (3) to 84 (4)
Pariente, 198523 6YesCaptopril 25 orallyIn 4 remained <5 μmol/min. In 2, drop from 198 and 200 to <5 μmol/min9.3 (23) to 71 (2.4)1-150 1.9 (0.4) to 1 (0.4) ml/min1-150 87 (10.6) to 72.5 (7.3)1-150
Daskalopoulos, 198724 11YesCaptopril 50–150 orally2.7 (1) to 0.48 (0.21) mmol/h1-150 Inulin clearance 73 (8) to 76 (7)377 (55) to 182 (42) ml/h1-150 88 (1) to 74 (1)1-150
Ohnishi, 199022 8YesCaptopril 50 orally114.8 (12.2) to 85.6 (10.2) mmol/dayNA1800 (170.6) to 1422 (143.2) ml/day90.5 to 761-150
8YesEnalapril 10 orally103.2 (12.1) to 113.7 (32.7) mmol/day1-151 NA1940 (168.3) to 2192.5 (226.9) ml/day1-151 92.7 to 821-150
Gentilini, 199325 30Yes (n=9)Captopril 12.5 intravenous43.8 (placebo) v 30.6 (drug) μmol/min1-150 108 (7) (placebo) v 78 (9) (drug)1-150 2.7 (0.7) (placebo) to 2.1 (0.4) (drug) ml/minReduction <5
No (n=21)Captopril 12.5 intravenous40.3 (6.1) (placebo )v 29.3 (7.6) (drug) μmol/min1-150 102 (4) (placebo) v 88 (3) (drug)1-150 3.9 (0.3) (placebo) to 4.2 (0.3) (drug) ml/minReduction <5

  • Values are mean (SD).

  • NA, data not given in the studies or not applicable; GFR, glomerular filtration rate; MAP, mean arterial pressure.

  • ↵1-150 Statistically significant compared with baseline;

  • ↵1-151 statistically significant compared with captopril.